Therapeutic utilities of fibroblast growth factor 19
Authors:
- 3 October 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 15 (11) , 1307-1316
Abstract
Diabetes and associated metabolic conditions have reached pandemic proportions worldwide and there is a clear unmet medical need for new therapies that are both effective and safe. FGF19 is a distinctive member of the FGF family that functions as an endocrine hormone. An up-to-date report on the exciting findings related to the involvement of FGF19 in the regulation of glucose, bile acid metabolism and energy expenditure. The role of FGF receptors in these different activities. The therapeutic potential of FGF19 and the engineering opportunities for removing undesirable mitogenic activity. The ability of FGF19 to regulate bile acid homeostasis, gallbladder filling and tumor development and its potent ability to normalize glucose, lipid and energy homeostasis have made it a potential therapeutic target for the treatment of patients with gallstones, cancer and metabolic diseases, among others. Its potential utility as a novel therapeutic for both type 1 and type 2 diabetes is of particular interest. The ability to separate the undesired mitogenic activity from its potent metabolic activities has opened new opportunities for the development of potential therapeutic molecules based on FGF19 in treating various conditions associated with metabolic syndrome.Keywords
This publication has 46 references indexed in Scilit:
- Hormone-like fibroblast growth factors and metabolic regulationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Advanced hepatocellular carcinoma. Review of targeted molecular drugsAnnals of Hepatology, 2011
- The role of signaling pathways in the development and treatment of hepatocellular carcinomaOncogene, 2010
- FGFs and metabolismCurrent Opinion in Pharmacology, 2009
- Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob miceProceedings of the National Academy of Sciences, 2009
- The Klotho gene family as a regulator of endocrine fibroblast growth factorsMolecular and Cellular Endocrinology, 2009
- Actions and Mode of Actions of FGF19 Subfamily MembersEndocrine Journal, 2008
- Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily MembersMolecular and Cellular Biology, 2007
- Fibroblast Growth Factor 19 Increases Metabolic Rate and Reverses Dietary and Leptin-Deficient DiabetesEndocrinology, 2004
- Globalization, coca‐colonization and the chronic disease epidemic: can the Doomsday scenario be averted?Journal of Internal Medicine, 2000